Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab

BackgroundAcquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody, which is effective in treating aTTP episodes.Patients/MethodsHere we report on seven episodes of aTTP treated without plasma exchange in six female patients in Germany and Austria. Two...